Navigation Links
Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
Date:3/27/2013

HAYWARD, Calif., March 27, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced it has initiated the CHABLIS-SC1 Phase 3 study of blisibimod, a novel inhibitor of B-Cell Activating Factor (BAFF) for the treatment of systemic lupus erythematosus (lupus). Lupus is a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain and major organ complications.

The Phase 3 CHABLIS-SC1 study is a multicenter, placebo-controlled, randomized, double-blind study designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE (SELENA-SLEDAI > 10) who have not achieved optimal resolution of their disease with corticosteroid use. The study will enroll patients from Latin America, Asia Pacific and Commonwealth of Independent States who will be randomized to receive blisibimod or placebo for 52 weeks after which they will have the option to receive blisibimod therapy in an open-label, long-term, follow-up safety study. The study will enroll approximately 400 patients and the primary endpoint will be a Systemic Lupus Erythematosus Response Index-8 (SRI-8). An SRI-8 responder is defined as a patient who has achieved a reduction in SELENA-SLEDAI equal to or greater than 8 points, and no new BILAG A or two B organ domain scores, and no increase in Physician's Global Assessment (PGA) of greater than 0.3 on a three point scale. As part of the CHABLIS-SC1 clinical study an independent statistician will conduct interim analyses to validate key study assumptions.  A summary of these analyses will be published later in 2013.

The design of the CHABLIS-SC1 s
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 3, 2015  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... treating opioid overdose with intranasal naloxone, has commenced ... (NDA) to the United States Food and Drug ... naloxone, a drug intended to treat opioid overdose. ...
(Date:6/3/2015)... BARBARA, Calif. , June 3, 2015  The ... formal endorsement of a Midwife Kit as a standard ... Kit was developed by Direct Relief in consultation with ... of charge to midwives in developing countries. ... from complications related to their pregnancy or childbirth.  Skilled ...
(Date:6/3/2015)... , June 3, 2015 ... "Interventional Cardiology & Peripheral Vascular Devices Market (Embolic ... Catheters, EVAR Stent Grafts, IVC Filters, Stents, Balloons ... MarketsandMarkets, the Interventional Cardiology and Peripheral Vascular Devices ... by 2019 with a CAGR of 7.4% from ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 4The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4
(Date:6/3/2015)... (PRWEB) June 03, 2015 VeoMed ... to expand online and mobile access to premier ... and Maintenance of Certification (MOC) activities. ... VeoMed’s innovative courses to Decker’s extensive lists of ... in purchasing access to VeoMed’s premier online and ...
(Date:6/3/2015)... Texas (PRWEB) June 03, 2015 ... and Analytics solutions, today announced the launch of ... EXtensions (DSX) for SAP® BusinessObjects™ Design Studio. The ... additional visualization capabilities and advanced functionalities into their ... the DSX suite, Visual BI is adding key ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 According to ... police officers intercepted fake oxycodone pills which actually ... were doctored to look legitimate, and even sported the ... are warning those consuming 30 mg oxycodone to be ... pills online or buy them illegally on the street. ...
(Date:6/3/2015)... 2015 These are challenging and unpredictable ... growing number of digital-first business are rewriting the rules ... a serious need for traditional businesses to take on ... and deliver their services. On top of this ... and technology start-ups, to bring new innovation and approaches ...
(Date:6/3/2015)... June 03, 2015 Fit Body Boot ... camp fitness program. The company helps thousands of individuals across ... encourage more people to hit the gym and get the ... tips for getting the most out any gym membership: , ... about committing to gym memberships is saying motivated and on ...
Breaking Medicine News(10 mins):Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2Health News:Summer Body Slim-Down: 5 Ways to Avoid Quitting Gym Memberships this Summer 2Health News:Summer Body Slim-Down: 5 Ways to Avoid Quitting Gym Memberships this Summer 3
... CHICAGO Results of a randomized, controlled clinical trial presented ... North America (RSNA) reveal that one in five patients with ... legs and other parts of the body also have significant ... (PAD) occurs when plaque, a combination of fat, cholesterol and ...
... St. Louis, MO, December 1, 2009 Adolescent obesity is ... every three children, resulting in 4-5 million overweight youth in ... 2009 issue of the Journal of the American Dietetic ... dietary intake and physical activity, comparing overweight adolescents who lost ...
... ... treatments and send patients home pregnant with multiples. While they want to achieve a ... mindful of the burden multiple births can put on a country’s healthcare system. , ... (PRWeb UK) November 30, 2009 -- ...
... , CHICAGO, Dec. 1 Results of a randomized, controlled ... Radiological Society of North America (RSNA) reveal that one in ... blood to the legs and other parts of the body ... Peripheral arterial disease (PAD) occurs when plaque, a combination of ...
... CHICAGO, Dec. 1 High-frequency ultrasound with elastography can ... to a study presented today at the annual meeting ... "High-frequency ultrasound with elastography has the potential to improve ... Eliot L. Siegel, M.D., vice chairman of the Department ...
... , CHICAGO, Dec. 1 A study presented ... North America (RSNA) revealed that MRI is a highly accurate ... common condition that is the leading cause of death for ... to the increase in cesarean sections and other surgeries that ...
Cached Medicine News:Health News:Severe asymptomatic heart disease may accompany narrowing in leg arteries 2Health News:Investigators identify successful weight control strategies for adolescents 2Health News:East Coast Fertility Aims to Build Families One Baby at a Time by Applying Single Embryo Transfers to Donor Egg Program 2Health News:East Coast Fertility Aims to Build Families One Baby at a Time by Applying Single Embryo Transfers to Donor Egg Program 3Health News:Severe Asymptomatic Heart Disease May Accompany Narrowing in Leg Arteries 2Health News:Severe Asymptomatic Heart Disease May Accompany Narrowing in Leg Arteries 3Health News:Special Ultrasound Accurately Identifies Skin Cancer 2Health News:Special Ultrasound Accurately Identifies Skin Cancer 3Health News:MRI Helps Detect Life-Threatening Pregnancy Complication 2Health News:MRI Helps Detect Life-Threatening Pregnancy Complication 3
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
... instrument introduction. The dual knobs allow ... and removed. The maximum diameter of ... introduced should be measured to ensure ... sterile in peel-open packages. Intended for ...
... to provide urethral drainage ... repair. The C-shape allows ... close during postoperative swelling ... maintaining urethral patency. Supplied ...
Medicine Products: